Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment
- 1 January 2012
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 23 (1), 139-140
- https://doi.org/10.1097/cad.0b013e32834be51a
Abstract
A patient with metastatic ovarian cancer was treated with liposomal doxorubicin and carboplatin. She had an extravasation during liposomal doxorubicin infusion. Initially, she was treated conservatively with cold compresses and topical treatment. However, because of worsening of symptoms, she received dexrazoxane once daily for 3 days after which complete recovery occurred. This is the first casereport on symptomatic extravasation of liposomal doxorubicin treated with dexrazoxane.Keywords
This publication has 9 references indexed in Scilit:
- Zytostatikainduzierte ParavasateMedizinische Klinik, 2010
- Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancerCritical Reviews in Oncology/Hematology, 2010
- European Oncology Nursing Society extravasation guidelinesEuropean Journal of Oncology Nursing, 2008
- Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline ChemotherapyThe Oncologist, 2008
- Management of Anthracycline Extravasation InjuriesAnnals of Pharmacotherapy, 2007
- Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studiesAnnals of Oncology, 2006
- Extravasation: a dreaded complication of chemotherapyAnnals of Oncology, 2003
- Five-year leukemia survival by ageAnnals of Oncology, 1999
- Lack of Vesicant Injury Following Extravasation of Liposomal DoxorubicinJNCI Journal of the National Cancer Institute, 1995